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MicroRNA-24 Regulates Vascularity After
Myocardial Infarction
Jan Fiedler, PhD; Virginija Jazbutyte, PhD; Bettina C. Kirchmaier, PhD; Shashi K. Gupta, MSc;
Johan Lorenzen, MD; Dorothee Hartmann, MSc; Paolo Galuppo, PhD; Susanne Kneitz, PhD;
John T.G. Pena, MD; Cherin Sohn-Lee, PhD; Xavier Loyer, PhD; Juergen Soutschek, PhD;
Thomas Brand, PhD; Thomas Tuschl, PhD; Joerg Heineke, MD; Ulrich Martin, PhD;
Stefan Schulte-Merker, PhD; Georg Ertl, MD; Stefan Engelhardt, MD, PhD;
Johann Bauersachs, MD; Thomas Thum, MD, PhD
Background—Myocardial infarction leads to cardiac remodeling and development of heart failure. Insufficient myocardial
capillary density after myocardial infarction has been identified as a critical event in this process, although the
underlying mechanisms of cardiac angiogenesis are mechanistically not well understood.
Methods and Results—Here, we show that the small noncoding RNA microRNA-24 (miR-24) is enriched in cardiac
endothelial cells and considerably upregulated after cardiac ischemia. MiR-24 induces endothelial cell apoptosis,
abolishes endothelial capillary network formation on Matrigel, and inhibits cell sprouting from endothelial spheroids.
These effects are mediated through targeting of the endothelium-enriched transcription factor GATA2 and the
p21-activated kinase PAK4, which were identified by bioinformatic predictions and validated by luciferase gene reporter
assays. Respective downstream signaling cascades involving phosphorylated BAD (Bcl-XL/Bcl-2–associated death
promoter) and Sirtuin1 were identified by transcriptome, protein arrays, and chromatin immunoprecipitation analyses.
Overexpression of miR-24 or silencing of its targets significantly impaired angiogenesis in zebrafish embryos. Blocking
of endothelial miR-24 limited myocardial infarct size of mice via prevention of endothelial apoptosis and enhancement
of vascularity, which led to preserved cardiac function and survival.
Conclusions—Our findings indicate that miR-24 acts as a critical regulator of endothelial cell apoptosis and angiogenesis
and is suitable for therapeutic intervention in the setting of ischemic heart disease. (Circulation. 2011;124:720-730.)
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M
yocardial infarction (MI) is a leading cause of morbid-
ity and mortality worldwide. MI leads to scar forma-
tion and left ventricular remodeling, including cardiac dila-
tation, contractile dysfunction, cardiomyocyte hypertrophy,
and fibrosis.1 Tissue hypoxia triggers endothelial apoptosis,
and insufficient capillary density further contributes to an
increase of infarct size and left ventricular dysfunction.2–4
Clinical Perspective on p 730
MicroRNAs (miRNAs) are endogenous small noncoding
RNA molecules that regulate a substantial fraction of the
genome by binding to the 3 untranslated region (3UTR) of
frequently coordinately acting target messenger RNAs.5
MiRNAs have been identified as valuable therapeutic targets in
a variety of diseases, including cardiovascular disease.6–12
Inhibition of miRNA processing by genetic knockdown of
Dicer expression impairs endothelial functions and angiogen-
esis.13–15 Certain miRNAs are important regulators of endo-
thelial function, especially angiogenesis.7,13–17 A subset of
miRNAs is regulated by tissue oxygen levels, and miR-24 is
activated by hypoxic conditions via the hypoxia-inducible
factor 1 (HIF-1).18 Although miR-24 is expressed in a variety
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the cardiovascular system remains basically uncertain. Here,
we show that miR-24 acts as a critical regulator of endothelial
cell apoptosis and angiogenesis and is suitable for therapeutic
intervention in the setting of ischemic heart disease.
Methods
miRNA/RNA Isolation, miRNA Reverse
Transcription–Polymerase Chain Reaction, and
Global Transcriptome Analysis
RNA isolation was performed with TRIzol reagent (Invitrogen) or
the miRVana miRNA Isolation Kit (Ambion) according to the
manufacturer’s instructions. For detection of miRNAs in samples,
different TaqMan miRNA assays (Applied Biosystems) were applied
(online-only Data Supplement Table I). The small RNA molecule U6
small nuclear (Rnu6–2) was amplified as a control. Reverse tran-
scription–polymerase chain reaction analysis was performed in an
ICycler (Bio-Rad). To assess RNA integrity for downstream array
analysis, total RNA was subjected to capillary chromatography in an
Agilent bioanalyzer 2100. Gene array analysis was performed with
the Affymetrix GeneChip system according to the manufacturer’s
instructions and with Human Gene 1.0ST arrays (Affymetrix Sys-
tems). Further microarray analyses and data handling were per-
formed as described previously.21
Transfection Assays
Transient liposomal transfection of small inhibitory RNAs (siRNAs)
or miRNAs was performed according to the manufacturers’ instruc-
tions. Briefly, cells were split 1 day before transfection to reach 60%
to 70% confluence on the day of transfection. Specific siRNAs/
miRNAs and control siRNA/miRNA and Lipofectamine 2000 (In-
vitrogen) were mixed separately and incubated for 5 minutes with
Opti-MEM I media (Invitrogen). Complexes were added together
and incubated for 20 minutes. Media were changed to antibiotic-free
media before the addition of liposomal siRNA complexes (final
concentration 150 nmol/L for siRNA and 100 nmol/L for miRNAs).
Cells were incubated for 4 hours before the media were changed to
fresh media. Silencing of proteins or miRNA targets was monitored
for 48 hours (siRNA) or 72 hours (miRNAs) after transfection by
Western blot analysis. Specific details about the siRNAs and
miRNAs used are given in Table II in the online-only Data
Supplement.
Apoptosis Detection
Apoptosis was measured with the Annexin-V-Fluos kit from Roche
Diagnostics (Penzberg, Germany) according to the manufacturer’s
instructions and as described previously.6 Detection of apoptosis
was either done by fluorescent-activated cell sorter analysis on a
FACSCalibur (BD Biosciences) or by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) assays.
Western Blotting and ELISA
Western blot analysis was performed with 10 to 40 g of total
protein. Protein was blotted onto polyvinylidene fluoride membrane
in Mini Trans-Blot electrophoretic transfer cell (Bio-Rad). After-
ward, different antigens were detected by appropriate antibodies
(online-only Data Supplement Table III). For phosphorylated Bcl-
XL/Bcl-2–associated death promoter (phospho-BAD; Ser112) detec-
tion in cell culture samples, we applied a PathScan phospho-BAD
(Ser112) sandwich ELISA kit (No. 7182; Cell Signaling) according
to the manufacturer’s instructions. Phospho-BAD levels were related
to total BAD expression levels as obtained by Western blotting.
Analysis of Capillary and Arteriolar Density
Analyses of capillary and arteriolar density were performed in
transverse sections of the periinfarct zone and the remote zone from
left ventricles 14 days after MI. Capillary and arteriolar densities
were evaluated after fluorescent immunohistochemical staining for
platelet and endothelial cell adhesion molecule-1 (PECAM-1; endo-
thelial marker) or -smooth muscle actin (Acta2; smooth muscle
cells) with antibodies listed in online-only Data Supplement Table
III. Arterioles were recognized as vessels with 1 or more continuous
layer of Acta2
 vascular smooth muscle cells. The number of
capillaries and arterioles per square millimeter was counted in a
blinded fashion.
Tube Formation and Spheroid Formation Assay
Transfection or transduction of cultured cells was performed as
mentioned previously. Then, cells were harvested and 15 000 cells
were seeded on top of Matrigel-coated chamber slides (BD). After 6
to 8 hours and 24 hours, pictures were taken on a Zeiss AxioVision
microscope (Jena, Germany). In selected experiments, a pan-caspase
inhibitor (caspase 3 inhibitor I; Calbiochem; 100 mol/L, 72 hours)
was used. For spheroid formation, miRNA-transfected human um-
bilical vein endothelial cells were trypsinized and collected in
EBM-2 medium containing FCS and 20% Methocel (Sigma-Al-
drich). 500 cells in 100 l of medium were plated per well in a
96-well plate (U-shaped bottom) and cultivated overnight at 37°C,
5% CO2. The next day, spheroid formation was visualized by
microscopy on a Nikon ECLIPSE Ti at 10 or 20 magnification.
Spheroids were harvested at 200g and resuspended in a mixture of
80% Methocel and 20% FCS. Next, 50 spheroids per well were
distributed in a 24-well plate by taking 500 L of spheroid
suspension together with 500 L of collagen-containing matrix
(DMEM, collagen solution, and NaOH). After 30 minutes’ incuba-
tion at 37°C, 100 L of EBM-2 medium supplemented with 40%
FCS and basic fibroblast growth factor (30 ng/mL) was given on top
of casted gels. Twenty-four hours after initial seeding, endothelial
sprouts were fixed with 10% paraformaldehyde before sprouting
capacity was evaluated by microscopy.
Scratch Wound (Migration) Assay
Transfected human umbilical vein endothelial cells were cultivated
in EBM-2 medium at 37°C, 5% CO2. The scratches in the cell
monolayer were generated with a 100-L tip, and the cells were
photographed at 0, 8, and 24 hours with a Zeiss Axiovert 135
microscope. Subsequently, the distance between cell fronts was
measured with an AxioVision documentation system (Zeiss).
Proliferation Assays
To measure proliferative capacity in miRNA-modulated cells, a
WST-1 (Roche) or standard bromodeoxyuridine proliferation assay
(Calbiochem) was applied. MiRNA transfection was performed as
mentioned under Transfection Assays. Next, medium was changed
and replaced by WST-1 or bromodeoxyuridine reagent as instructed
by the manufacturer. WST-1 and bromodeoxyuridine absorbances
were measured at 450 and 340 nm, respectively.
Luciferase Reporter Assays
A luciferase reporter assay system was applied to validate potential
miRNA targets as described previously.6 A putative 3UTR miRNA
binding sequence was cloned into the SpeI and HindIII cloning site
of pMIR-REPORT vector (Ambion). Mutations in the putative
miR-24 binding sites were introduced by site-directed mutagenesis
(Quick Change II–Site-Directed Mutagenesis Kit; Stratagene). The
mutations within the 3UTRs were as follows (8-mer/7mer-8m seed
in bold, mutated nucleotides underlined): GATA2 wild-type: 5-
CAGGCTGGGCTGAGCCAAAGCCAGAGTG-3, GATA2 mu-
tant 5-CAGGCTGGGCTGGTACAAAGCCAGAGTG-3; PAK4
wild-type 5-CCTCTCCCCCTGAGCCATTGGGGGGGTC-3,
PAK4 mutant 5-CCTCTCCCCCTGCTCCATTGGGGGGGTC-3;
RASA1 wild-type: 5-TTAACAACCTCTGAGCCTTGGTGTA
CAG-3,RASA1mutant5-TTAACAACCTCTGGACCTTGGTGTA
CAG-3;H2AFXwild-type(2sites):5-CTGGACTGAGCCT C…T G
TATGCTATCTGAGCCGTCT-3.
The resulting construct was cotransfected with the miRNAs of
interest and a -galactosidase control plasmid (Promega) into
HEK293 reporter cells in 48-well plates by use of Lipofectamine
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miRNA was applied. Cells were incubated for 24 hours before
luciferase and -galactosidase activity was measured (Promega).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was used to detect protein-
DNA interactions. We applied a ChIP protocol from Weinmann et
al22 with modifications and bioinformatic predictions23, 24 as detailed
in the online-only Data Supplement. The oligonucleotide primer
sequences used are given in online-only Data Supplement Table IV.
Viral Transduction
The original green fluorescent protein (GFP)–murine-GATA2 plas-
mid was a gift from Marjo Simonen (Novartis, Basel, Switzerland).
N-terminal GFP-tagged GATA2 was subcloned in an appropriate
adenoviral entry vector. Adenoviruses were generated with the
Gateway system (Invitrogen) by polymerase chain reaction amplifi-
cation of the human cDNA sequence and recombination into the
pAd/CMV/V5 destination vector (Invitrogen). Subsequently, 15 g
of purified recombinant adenoviral DNA was digested with PacI and
precipitated with sodium acetate. One microgram of linearized
vector was transfected to HEK 293 cells (Invitrogen) with Effectene
reagent (Qiagen). After 3 amplifications, adenoviruses were purified
and titrated with the Adeno-X Maxi purification kit and rapid titer kit
(Clontech). For viral transduction experiments, cells were grown to
subconfluence and infected with viral particles for 4 hours before the
medium was changed. The multiplicity of infection was 4 to 40. A
yellow fluorescent protein control virus was also applied with same
multiplicity of infection.
In Vivo Studies
The studies conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH publication No. 85-23, revised 1996).
Zebrafish Assays
Zebrafish wild-type TU and TL lines and the transgenic line
Tg(kdrl:eGFP)
s843 were kept at 28.5°C and staged as described
previously.25 To inhibit pigmentation, 0.003% 1-phenyl-2-thiourea
was added to the embryo medium. Embryos were injected at the 1-
to 2-cell stage with 2 nL of pre-miR-24 (25 mol/L) or control
pre-miRs (25 mol/L). Injected embryos were analyzed 48 hours
after fertilization (hpf). Images of living embryos were acquired with
Leica MZ FLIII or Olympus SZX16 microscopes.
Morpholino-modified oligomers (MOs) were obtained from Gene
Tools, LLC (Philomath, OR) and diluted in water containing 0.2%
phenol red. Morpholino sequences are listed in online-only Data
Supplement Table V. For control purposes, a standard control MO
oligomer (MO-control; Gene Tools) was injected at the same
concentration as a negative control. One- to 2-cell stage embryos
were injected with previously validated 0.2 mmol/L MO1-gata2a26
or 0.4 mmol/L MO2-gata2a.27 In the case of pak4, morpholinos were
designed against the ATG (MO1-pak4) and the fifth exon/intron
boundary (MO2-pak4). One- to 2-cell stage embryos were injected
with 2 to 4 ng of MO1-pak4 or 4 to 8 ng of MO2-pak4, respectively.
Morpholino knockdown efficiency for start-site–targeting morpholi-
nos was tested as recommended before by an in vivo translation-
blockage assay. For the splice-site–targeting morpholino, MO2-pak4
knockdown efficiency was tested by RNA isolation from
morpholino-injected zebrafish with TRIzol (Invitrogen) and subse-
quent cDNA from DNase-treated total RNA with M-MLV (Moloney
murine leukemia virus) reverse transcriptase (Promega). Primers
used for reverse transcriptase polymerase chain reactions are avail-
able on request.
For confocal analyses, zebrafish embryos were fixed at 48 hpf in
a 4% paraformaldehyde solution overnight and embedded in 1.5%
low melting point agarose. Confocal images were obtained with a
Leica TCS SP2 confocal laser scanning microscope. The maximum
projection algorithm of the Leica software was then used to calculate
information sectored in different ranks to a 2-dimensional projection.
Myocardial Infarction
Male mice (C57BL/6, 8 to 10 weeks old) underwent coronary artery
ligation for the production of MI as described previously.28 Cardiac
dimensions and function were analyzed by pulse-wave Doppler
echocardiography essentially as described previously.29 Further de-
tails are given in the online-only Data Supplement.
Statistical Analysis
Average data are presented as mean and SEM unless otherwise
stated. Statistical analysis was performed with the StatView (SAS
Institute) package. For statistical comparison of 2 groups, we used an
unpaired 2-tailed Student t test; for the comparison of 3 or more
groups, we used ANOVA followed by Bonferroni post hoc test.
Differences were considered significant when P0.05. In the Fig-
ures, probability values are indicated by 1 (P0.05), 2 (P0.01), or
3( P0.005) asterisks.
Please see the online-only Data Supplement for further details of
the methods and materials used.
Results
MiR-24 Is Upregulated in Endothelial Cells by
Cardiac Ischemia
A spatiotemporal analysis of miR-24 expression in fraction-
ated cardiac cell types demonstrated selectively strong induc-
tion of miR-24 in endothelial cells isolated from ischemic but
not remote myocardium early after MI (Figure 1A). Accord-
ingly, costaining of mouse cardiac MI sections after in situ
hybridization with fluorescein isothiocyanate–conjugated
anti-miR-24 probes with cell-type–specific antibodies dem-
onstrated specific enriched endothelial but not smooth muscle
cell miR-24 expression in infarcted cardiac areas (Figures 1B
and C). The hybridization signal was abolished when a
hybridization probe with similar melting temperature but
targeted against a scrambled sequence was used (data not
shown). In line with the in situ hybridization experiments
after ischemic cardiac injury, hypoxic culture conditions
increased miR-24 expression in endothelial cells (Figure 1D).
MiR-24 Triggers Endothelial Apoptosis and
Impairs Angiogenesis
To characterize miR-24 function, we overexpressed synthetic
miR-24 precursors in human umbilical vein endothelial cells.
MiR-24 overexpression induced apoptosis in endothelial
cells, whereas miR-24 antagonism reduced apoptosis (Figure
2A). Hypoxia-induced apoptosis of endothelial cells was
attenuated by blocking endogenous miR-24, whereas overex-
pression of miR-24 with synthetic precursors exaggerated
endothelial apoptosis (Figure 2B). MiR-24 attenuated tube
formation (81%; P0.0001) independently from its pro-
apoptotic effects, which suggests the potential involvement of
multiple target networks (Figure 2C; online-only Data Sup-
plement Figure Ia). Endothelial spheroid formation, sprouting
capacity, migration in scratch wound assays, and proliferation
were also impaired by miR-24 (Figures 2C through 2E).
GATA2 and PAK4 Are Targets of miR-24
To identify miR-24 targets that trigger endothelial apoptosis
and impair angiogenic properties, we first used bioinformat-
ics miRNA target prediction tools and detected a substantial
number of genes with putative 3UTR binding sites for
miR-24 that encompassed important functional roles in en-
722 Circulation August 9, 2011
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tion factor GATA2 and the p21-activated kinase PAK4, both
of which have established roles in vascular biology.30,43,44 To
validate those targets, primary endothelial cells were first
transfected with miR-24 precursors. This resulted in repres-
sion of GATA2 and PAK4 protein expression. PAK4 was
additionally repressed at the mRNA level (Figure 3A and data
not shown). Inhibition of miR-24 in endothelial cells by
specific antagonists increased GATA2 and PAK4 expression
(data not shown).
When we fused the respective 3UTR regions to a lu-
ciferase reporter gene and determined luciferase activity in
cells transfected with synthetic miR-24 precursors, miR-24
significantly repressed luciferase activity, whereas unrelated
miRNAs showed no effect (Figure 3B). We thus identified
GATA2 and PAK4 as direct targets of miR-24. Bioinformatic
miR-24 target prediction identified further potential targets
(Table). We also validated the RAS p21 protein activator
RASA1 and the histone coding gene H2AFX, because of its
described role in tumor vascularization.35 Overexpression of
miR-24 in endothelial cells reduced RASA1 and H2AFX
protein expression, and luciferase gene reporter assays iden-
tified them as direct miR-24 targets (online-only Data Sup-
plement Figures IIa and IIb). Functionally, RASA1 silencing
induced modest endothelial apoptosis but did not alter tube
formation, whereas no effects were seen after H2AFX down-
regulation (online-only Data Supplement Figures IIc through
IIe). In strong contrast, silencing of both GATA2 and PAK4
in endothelial cells by siRNA abrogated tube formation
Figure 1. Selective miR-24 upregulation in endothelial cells after
myocardial infarction (MI). A, Expression of miR-24 relative to
Rnu6–2 in fractionated endothelial cells (magnetic afﬁnity cell-
sorted CD146
 cells), cardiac ﬁbroblasts, and cardiomyocytes
of the periinfarct (MI) or remote region 0, 1, 3, or 14 days after
MI in mice. In situ hybridization of miR-24 with ﬂuorescent
probes and costaining against (B) endothelial (platelet and en-
dothelial cell adhesion molecule-1 [Pecam1]) and (C) smooth
muscle cell (Acta2) markers in mice after MI. D, Expression of
miR-24/RNU6–2 in human umbilical vein endothelial cells 24
hours after normoxic (21% O2) or hypoxic conditions (1% O2).
n3 to 7 per experiments or animals per group. Data are mean
and SEM; *P0.05, ***P0.005. FC indicates fold change.
Figure 2. Activation of endothelial apoptotic programs and
impairment of angiogenic properties by miR-24. A, Relative
changes of apoptotic cells 72 hours after transfection of human
umbilical vein endothelial cells with scrambled-miR (scr), syn-
thetic mir-24 precursors (pre-24), or miR-24 antagonists (anti-
24). B, Changes of apoptotic endothelial cells after transfection
with scr-miR, pre-miR-24, or anti-miR-24 for 72 hours and sub-
sequent exposure to hypoxia (1% O2, 24 hours) or normoxia
(21% O2, 24 hours). C, Tube formation (top), spheroid formation
(middle), and sprouting (bottom) capacity of human umbilical
vein endothelial cells 72 hours after transfection with scr-miR,
pre-miR-24, or anti-miR-24. D and E, Migratory (scratch wound
assay; D) and proliferation (bromodeoxyuridine assay; E) capac-
ity of human umbilical vein endothelial cells 72 hours after trans-
fection with miR-24 or scrambled controls. n3 to 4 experi-
ments per group. Data are mean and SEM; *P0.05,
**P0.01,***P0.005.
Fiedler et al MicroRNA-24 Regulates Vascularity 723
 by guest on August 25, 2011 http://circ.ahajournals.org/ Downloaded from capacity and significantly induced apoptosis (Figures 3C and
3D). Immunohistochemical and Western blotting analyses
revealed enriched cardiac endothelial expression of GATA2,
PAK4, and RASA1 (online-only Data Supplement Figures
IIIa and IIIb), which suggests cell-type specific coexpression
of miR-24 with those targets within the heart.
Downstream GATA2 and PAK4 Target Regulation
To understand the observed cellular changes in miR-24 target
regulation, we further investigated the downstream signaling
cascades of the direct miR-24 targets GATA2 and PAK4.
First, we used a global transcriptome analysis after viral
overexpression or silencing of GATA2 in endothelial cells
Table. Predicted microRNA-24 Target Messenger RNAs
Gene
Symbol Gene Name
Endothelial
Expression
Observed
(Reference)
Evolutionary
Conserved No.
of Species
(miRBase)
Predicted
Target
(miRBase)
Predicted
Target
(PicTar)
Seed Match for
miR-24 (TargetScan)
GATA2 Endothelial transcription factor GATA2 30 4 Yes No 8mer
PAK4 Serine/threonine-protein kinase PAK4 31 5 No Yes 8mer
RASA1 Ras GTPase-activating protein 1 32 10 No Yes 8mer
CDKN1B Cyclin-dependent kinase inhibitor
1B (p27Kip1)
33 4 No Yes 8mer
AMOTL2 Angiomotin like 2 34 3 No Yes 8mer
H2AFX Histone family, member X 35 5 Yes Yes 7mer
RAP1B RAP1B, member of RAS oncogene
family
36 5 No Yes 8mer
AXL AXL receptor tyrosine kinase 37 8 No Yes 7mer
S1PR1 Sphingosine-1-phosphate receptor 1 38 NA NA NA 8mer
MAGI1 Membrane associated guanylate kinase,
WW and PDZ domain containing 1
39 5 No NA 8mer
TFPI Tissue factor pathway inhibitor 40 5 No NA 8mer
ANGPT4 Angiopoietin 4 41 5 No NA 8mer
BMPR2 Protein receptor, type II 42 6 No No 7mer
The microRNA databases and target prediction tools miRBase (http://microrna.sanger.ac.uk/), PicTar (http://pictar.mdc-berlin.de/), and TargetScan (http://
www.targetscan.org/index.html) were used to identify potential microRNA-24 targets. NA indicates not available.
Figure 3. MiR-24 regulates GATA2 and
PAK4 in endothelial cells. A, Protein
expression of GATA2, PAK4, and
GAPDH 72 hours after transfection with
scrambled miRNAs (scr-miR) or syn-
thetic miR-24 precursors (pre-miR-24) to
human umbilical vein endothelial cells
and statistical summary. B, Activities of
luciferase reporter constructs comprising
the 3UTR regions of GATA2 and PAK4
mRNA relative to -Gal control plasmids
after transfection of synthetic miRNAs.
mut indicates mutant. C, Tube formation
of HUVECs after transfection of scram-
bled small inhibitory RNA (scr-siRNA) or
siRNA against GATA2 or PAK4 24 hours
after seeding on top of Matrigels and
statistical analysis. D, Apoptosis of en-
dothelial cells after transfection of
scrambled siRNA (scr-siRNA) or siRNAs
speciﬁc for GATA2 (siRNA-GATA2) or
PAK4 (siRNA-PAK4). Data are mean and
SEM; *P0.05, **P0.01,***P0.005.
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not shown) and identified 3 reciprocally regulated mRNAs
after GATA2 modulation (BMP and activin membrane-
bound inhibitor [BAMBI], endothelial cell–specific
molecule-1 [ESM1], and netrin-4 [NTN4]). Bioinformatics
studies identified BAMBI, ESM1, NTN4, heme-oxygenase-1
(HMOX1), and sirtuin-1 (SIRT1) as harboring GATA2 bind-
ing sites within their promoter sequence (data not shown). To
further validate GATA2-mediated regulation, we used
GATA2-ChIP and found those 5 mRNAs to be highly
enriched after ChIP (Figure 4A). GATA2 overexpression
strongly induced protein expression of SIRT1 and HMOX1
(both of which play important roles in angiogenesis45,46),
whereas siRNA-mediated GATA2 silencing reduced expres-
sion (Figure 4B; online-only Data Supplement Figures IVc
and IVd). HMOX1 was regulated by miR-24 via modulation
of GATA2 (Figure 4C; online-only Data Supplement Figures
Va and Vb). HMOX1 exerts vasoprotective and antiapoptotic
actions in endothelial cells,46 and consequently, we found
miR-24–mediated repression of HMOX1 resulted in en-
hanced reactive oxygen species formation in endothelial cells
(online-only Data Supplement Figure Vc), which may also
contribute to recent findings that miR-24 upregulation pre-
disposes cells to DNA damage.47
To identify proteins that further mediated the proapoptotic
action of endothelial miR-24, we hybridized endothelial
protein extracts after transfection of scrambled miRs or
synthetic miR-24 precursors to a protein microarray spotted
with antibodies for proteins involved in apoptosis (Figure
4D). A number of proapoptotic proteins were upregulated, eg,
HIF-1 (HIF-1a) and FAS, although we found a strong
reduction of BAD and HMOX1 (Figures 4C through 4E). The
direct miR-24 target PAK4 promotes BAD phosphorylation,
thus inactivating the proapoptotic protein BAD.48 MiR-24
overexpression led to a reduction of phosphorylated BAD
(pBAD), whereas miR-24 antagonism increased the pBAD/
BAD ratio (Figure 4E). Repression of PAK4 resulted in
reduced BAD phosphorylation (Figure 4F; online-only Data
Supplement Figure IVa), which contributed to increased
apoptosis in endothelial cells (Figure 3D). We also blocked
miR-24 expression to derepress PAK4, which resulted in
enhanced pBAD levels (Figure 4E). Knockdown of PAK4 led
to reduced pBAD levels in the absence or presence of miR-24
blockade, which suggests that PAK4 is a main modulator of
miR-24–mediated BAD phosphorylation in endothelial cells
(online-only Data Supplement Figure VD).
To test whether the miR-24 targets GATA2, PAK4, and
HMOX1 are among the main mediators of the antiangiogenic
and proapoptotic action of miR-24 in endothelial cells, we
reconstituted those targets in miR-24–overexpressing endo-
thelial cells. Reconstitution of miR-24–resistant GATA2,
PAK4, and HMOX1 rescued both miR-24–mediated endo-
thelial apoptosis and miR-24–impaired tube formation capac-
ity (Figures 4G and 4H). We thus identified a network of
Figure 4. GATA2, PAK4, and their down-
stream targets are involved in the action of
miR-24 in endothelial cells. A, Chromatin
immunoprecipitation of several DNA
sequences by GATA2 (GATA2-IP) compared
with appropriate controls. B, Heme oxygen-
ase 1 (HMOX1, left) expression in endothelial
cells after GATA2 or (C) miR-24 modulation.
D, Signal intensity of 35 different apoptosis-
related proteins (in duplicates) on Proteome
Proﬁler Array membranes (left) and statistical
summary (right) after hybridization of endo-
thelial protein extracts 72 hours after trans-
fection with scrambled-miRNAs (scr-miR) or
synthetic miR-24 precursors (pre-miR-24). E,
Ratio of phospho-BAD (Bcl-XL/Bcl-2–asso-
ciated death promoter; measured by ELISA)
relative to BAD expression (measured by
Western blot) in endothelial cells 72 hours
after transfection with scr-miR, pre-miR-24,
or anti-miR-24. F, pBAD/BAD ratio in endo-
thelial cells 48 hours after transfection of
scrambled siRNA (scr-siRNA) or siRNA
against PAK4 (siRNA-PAK4). si-scr indicates
scrambled siRNA. G, TUNEL assay was
used to detect apoptotic cells and (H) total
endothelial tube length 48 hours after trans-
fection of miR-24 precursors (pre-24) to pre-
transfected (24 hours; yellow ﬂuorescent
protein [YFP] control construct, GATA2-,
PAK4, and/or HMOX-1 construct; each miR-
24-resistant) human endothelial cells. a.u.
indicates arbitrary units. n3 to 6 experi-
ments per group. Data are mean and SEM;
*P0.05, **P0.01, ***P0.005.
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and angiogenic properties of endothelial cells. These impor-
tant cellular characteristics may affect (neo)vascularization in
vivo, especially after ischemic events.
MiR-24 Overexpression and Knockdown of
miR-24 Targets Impair Zebrafish
Vascular Development
To analyze miR-24 effects in vivo, we first injected miR-24
precursors into Tg(kdrl:eGFP)
s843 zebrafish embryos that
express GFP in the vasculature. Embryos at 48 hpf had
increased miR-24 expression levels (Figure 5A), as well as
abnormal vessel architecture and insufficient blood transport,
which demonstrates that miR-24 activation results in a robust
vascular phenotype, although we cannot exclude other cell-
type–specific effects (Figures 5B through 5I). To test the
involvement of the direct miR-24 targets Gata2 and Pak4 in
this model, we used target knockdown experiments.
Morpholino-based knockdown of the target gene gata2a
(Figures 5L and 5N), as well as pak4 (Figures 5P and 5R;
online-only Data Supplement Figure VI), led to blood accu-
mulation and pericardial edema compared with controls
(Figure 5J). Furthermore, confocal images of the trunk
vasculature revealed impaired vasculature formation. In
MO1-gata2a (Figure 5M), MO2-gata2a (Figure 5O), MO1-
pak4 (Figure 5Q), and MO2-pak4 (Figure 5S) embryos, we
observed near-identical phenotypes to the vascularization
defects seen in miR-24–overexpressing zebrafish. MiR-24–
overexpression phenotypes were slightly more severe than
single-gene knockdowns (eg, blood accumulation in the trunk
Figure 5. MiR-24 and its target genes
play a role in vascularization in vivo.
A–C, Forced expression of miR-24 in
zebraﬁsh embryos at 48 hours after fer-
tilization (hpf) via injection of miR-24 pre-
cursors. Statistical summary
(***P0.005) of ﬁsh embryos that devel-
oped pericardial edema/blood accumula-
tion defects (B) and vascular defects (C).
D–I, Lateral views of control (scrambled
sequence; D and E) and pre-miR-24–
injected (F–I) Tg(kdrl:eGFP)
s843 zebraﬁsh
embryos at 48 hpf. Embryos injected
with miR-24 precursors displayed
impaired and irregular vascularization
patterns (asterisks and arrows in
panels G and I). Pericardial edema and
blood accumulation was seen after
miR-24 overexpression (arrows in panels
F and H). J–S, Lateral views of
MO-control (J and K), MO-gata2a (L–O),
and MO-pak4 injected Tg(kdrl:eGFP)
s843
(P–S) zebraﬁsh embryos at 48 hpf.
Knockdown of the target genes gata2a
(L, N) and pak4 (P, R) mimicked miR-24
overexpression, with embryos that
lacked intersegmental vessels (asterisks
in G and S) and displayed shortened
intersegmental vessels (arrows in G, L,
M, O, and Q). Furthermore, blood accu-
mulation and pericardial edema were
observed in (M) MO1-gata2a,( O) MO2-
gata2a, (Q) MO1-pak4, and (S) MO2-
pak4 embryos, very similar to the vascu-
larization defects seen in embryos with
forced miR24 overexpression. Blood
accumulation and hemorrhaging were
more severe in MO-pak4 knockdown
embryos than in MO-gata2a injected
embryos (see also online-only Data Sup-
plement Figure VI D). ctr indicates
control.
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knockdowns; see also online-only Data Supplement Figure
VI D), which is to be expected given the simultaneous effect
of miR-24 on a number of genes.
Therapy With miR-24 Inhibitors Increases
Vascularization and Improves Cardiac Function
After MI
To further study the effects of miR-24 on vascularization in
mammals, we injected chemically engineered cholesterol-
conjugated single-strand RNA analogues (antagomirs) that
targeted miR-24 or scrambled controls into mice. In initial
experiments, we found Cy3-labeled antagomirs to be effec-
tively taken up by endothelial cells in vitro (Figure 6A).
Because we wanted to target mainly the endothelial cell
fraction, we first performed titration experiments with Cy3-
labeled antagomirs to achieve preferential delivery to endo-
thelial cells. Injection of a Cy3-labeled antagomir at a low
dose (5 mg/kg) mainly resulted in cellular uptake in cardiac
endothelial cells, whereas injection of a high dose (80 mg/kg)
led to a strong homogeneous uptake in all cardiac cells,
including cardiomyocytes (Figure 6B). Consequently, we
found injections of low doses of an antagomir (5 mg/kg, day
0 and day 2) against miR-24 to repress miR-24 but not
unrelated miRNAs mainly in fractionated endothelial cells
obtained from healthy or ischemic heart tissue (Figures 6B
and 6C and data not shown).
We then tested the effects of endothelial miR-24 antagonism
in a mouse model of MI. Immunohistochemical studies revealed
a greater amount of apoptotic endothelial cells in the periinfarct
zone (online-only Data Supplement Figure VII). In contrast,
endothelial apoptosis measured by TUNEL
/PECAM1
 cells
was reduced and both capillary and arteriolar density were
increased in the periinfarct region after miR-24 antagonism,
whereas no changes were observed in the remote myocardium
(Figure 7A; online-only Data Supplement Figure VII). Improved
capillary density correlated with significant smaller infarct size
14 days after MI (control 546% versus antagomir-24 383%,
P0.05).
MI led to an impairment of cardiac function 14 days after
intervention (Figure 7B). Systolic and diastolic left ventricu-
lar diameter and lung wet weight increased after MI (Figures
7C and 7D). In contrast, immediate treatment after MI with an
antagomir against miR-24 (days 0 and 2) improved cardiac
function and attenuated pulmonary congestion and left ven-
tricular dilatation (Figures 7B through 7E). Baseline data of
fractional shortening and left ventricular diameters were not
different between the investigated groups (data not shown).
Survival of MI animals was significantly improved by
miR-24 antagomir treatment (surviving animals at day 14:
scrambled antagomir 43.5% versus antagomir-24 78.3%;
P0.02). To exclude significant off-target effects and to
confirm specificity of antagomir-24, we injected an antago-
mir against a scrambled sequence, which did not affect
miR-24 expression or infarct healing (Figures 6C and 7B
through 7E). A schematic summary of our findings is pre-
sented as Figure 7F.
Discussion
In the present study, we identified miR-24 as a critical
regulator of endothelial cell survival and angiogenesis. We
found miR-24 to be enriched in cardiac endothelial cells and
to be upregulated after ischemic injury. However, miR-24 is
also expressed in other cells with different cell-specific
functions, such as insulin production of pancreatic -cells, in
part via regulation of the transcriptional repressor,49 cell cycle
regulation and proliferation of leukemia cells,50 and activa-
tion of smooth muscle cells via repression of Tribbles-like
protein 1.51 In the latter study, long-term hypoxia led to
miR-24 upregulation in lung tissue and to activation of lung
smooth muscle cells. Thus, inhibition of miR-24 in certain
pulmonary diseases may be of future therapeutic relevance.
With regard to function in other cardiac cell types, miR-24
Figure 6. Low-dose antagomir-24 treatment preferably leads to miR-24 silencing in endothelial cells in vitro and in vivo. A, Uptake of
Cy3-labeled antagomirs in human umbilical vein endothelial cells (10 g/mL, 24 hours). B, Primary deposition of Cy3-labeled antago-
mirs (Cy3-Ant.) to platelet and endothelial cell adhesion molecule-1 (Pecam1)–positive endothelial capillaries after injection of a low
dose (5 mg/kg) or homogenous cardiac uptake after treatment with 80 mg/kg (high dose). C, MiR-24 expression in fractionated cardio-
myocytes and cardiac endothelial cells 14 days after myocardial infarction (MI). Animals were treated at day 0 and day 2 with either 5
mg/kg scrambled antagomir (Scr) or antagomir against miR-24 (Ant24). n3 to 6 experiments/animals per group. Data are mean and
SEM; ***P0.005.
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hypertrophy in vitro,52 although a recent study revealed an
additional role in cardiomyocyte apoptosis.53 In that report,53
the authors described a downregulation of miR-24 in the
border zone after MI. In line with those results, we detected
a downregulation of miR-24 in fractionated cardiomyocytes
early after MI, whereas its expression was massively in-
creased in cardiac endothelial cells. We used post-MI treat-
ment with a low dose of an antagomir (25m g kg
1  d
1),
which silenced miR-24 specifically in endothelial cells but
not cardiomyocytes in the heart. Interestingly, high dosing of
an antagomir (280 mg  kg
1  d
1) against miR-24 had less
favorable effects on cardiac function after MI (data not
shown), which suggests potential toxicity of the high-dose
group or negative effects on cardiomyocyte biology, as
suggested recently.53 Future studies are therefore needed to
develop improved cell-type–specific delivery systems of
antagomirs. The role of miR-24 in other ischemic disease
conditions and its potential therapeutic value remain to be
investigated.
We used bioinformatics analyses to characterize the endo-
thelial miR-24 targetome. So far, we have identified GATA2
(via SIRT1 and HMOX1) and PAK4 (via pBAD) as major
miR-24 targets that control a complex network of apoptotic
and angiogenic programs in endothelial cells (Figure 7F).
However, many additional targets may be involved in the
action of miR-24, especially in other disease conditions in
which target availability may change. Although many other
targets might be involved, target reconstitution experiments
showed dominant roles of GATA2 and PAK4 for the proapo-
ptotic and antiangiogenic effects of miR-24. The role of other
potential targets important for miR-24 biological actions
remains to be elucidated.
Importantly, application of low-dose antagomirs permitted
silencing of miR-24 expression predominantly in endothelial
cells in vivo, which resulted in reduced endothelial apoptosis,
enhanced vascularization, decreased infarct size, and im-
proved cardiac function after MI. Thus, miR-24 and its
downstream targets may serve as valuable therapeutic entry
points to interfere with endothelial genetic programs and
Figure 7. Antagomir-24 treatment
improves vascularization and preserves
cardiac function after myocardial infarc-
tion. A, Left, capillary (platelet and endo-
thelial cell adhesion molecule-1
[Pecam1]) and arteriolar (Acta2) density
in cardiac sections of the periinfarct
region 14 days after myocardial infarc-
tion and after treatment with antagomirs
against a scrambled sequence (Scr) or
miR-24 (Ant24). Right, statistical sum-
mary of the number of Pecam1
 capil-
laries and Acta2
 arterioles in the
remote and periinfarct area. B, Cardiac
function as fractional shortening (FS)
measured by echocardiography 14 days
after sham operation or myocardial
infarction (MI). Diastolic (C) and systolic
(D) left ventricular diameter (LVd and
LVs, respectively). E, Lung wet weight
after sham operation or MI. F, Scheme
of miR-24–regulated targets and down-
stream signaling cascades. n6t o9
experiments/animals per group. Data are
mean and SEM; *P0.05,
**P0.01,***P0.005.
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ischemic injury.
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CLINICAL PERSPECTIVE
Ischemic heart disease is the leading cause of death worldwide, often presenting as acute myocardial infarction. Myocardial
infarction frequently progresses to the development of heart failure. Insufficient myocardial vascularization prevents
optimal blood support for cardiomyocyte survival, although the underlying mechanisms of cardiac vascularization are not
well understood. MicroRNAs are small RNA molecules regulating approximately half of the genome and recently have
emerged as powerful therapeutic targets for various heart diseases. We identified miRNA-24 (miR-24) as being activated
in cardiac endothelial cells after myocardial infarction, leading to endothelial cell apoptosis and abolishment of capillary
network formation. These effects are mediated through targeting of the endothelium-enriched transcription factor GATA2,
the p21-activated kinase PAK4, and the respective downstream signaling cascades. Blocking of endothelial miR-24 in a
mouse model of myocardial infarction limits myocardial infarct size by preventing endothelial apoptosis and enhancing
vascularity, which leads to preserved cardiac function and survival. Thus, miR-24 acts as a critical regulator of cardiac
vascularization and is suitable for therapeutic intervention in the setting of ischemic heart disease. Our findings may lead
to clinical applications, whereby miRNA modulators are used systemically or locally to improve vascularization in patients
after myocardial infarction.
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  SUPPLEMENTAL MATERIAL 
 
Expanded Methods and Results 
 
Cultivation of cardiovascular cells. Human umbilical vein endothelial cells (HUVECs) were 
cultured  in  EGM2  media  supplemented  with  10%  (v/v)  fetal  calf  serum  (FCS)  and 
supplements  (all  reagents  from  Cambrex  Lonza,  UK).  Cells  were  grown  in  a  humidified 
atmosphere at 5% CO2 and 37°C.  
 
Fractionation of cardiac cell types from heart tissue. The thorax of mice was opened and 
the aorta was cannulated. After washing with 37°C PBS, the heart together with the cannula 
was  removed  and  perfused  with  a  collagenase  solution  for  5  min  (Joklik  MEM  medium 
supplemented  with  10  mM  butanedione  monoxime,  20  µM  calcium  chloride,  1mg/ml 
collagenase II) as described 
1. Then the heart was placed in 37°C pre-warmed collagenase 
solution for further 25 min and was subsequently divided in infarct and remote areas, minced 
and filtered through a nylon mesh (200 µm pore size). Then, cardiomyocytes and cardiac 
fibroblasts  were  separated  by  a  sedimentation  step  as  described 
2.  Within  the  non-
cardiomyocyte  cell  fraction  retained  in  the  supernatant  an  incubation  step  with  CD146-
antibodies  coupled  to  microbeads  was  performed  and  subjected  to  magnetic  affinity  cell 
sorting  according  to  the  manufacturers’  recommendations  (Mouse  CD146  microbead 
endothelial isolation kit, Miltenyi Biotec, Germany).  
 
Apoptosis  protein  array.  Apoptosis  array  data  were  generated  by  applying  a  human 
apoptosis array kit (ARY009, R&D, USA). 200 µg protein from a pool of three samples were 
incubated with antibody-coated membranes following manufacturers´ instructions. Various 
regulated proteins were then validated by Western blotting. 
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Detection  of  reactive  oxygen  species  (ROS).  The  redox-sensitive,
  cell-permeable 
fluorophore  dihydroethidium  (DHE)  becomes  oxidized
  in  the  presence  of  O2
–  to  yield 
fluorescent ethidium.
 Thus, dye oxidation is an indirect measure of the presence of
 reactive 
oxygen intermediates 
3. MiRNA-transfected HUVECs were incubated with DHE (2.5 µM) for 
30 min.
 After washing, HUVECs were immediately analyzed with FACS (FACS Calibur, BD 
Bioscience). 
 
MircoRNA target prediction. The microRNA databases and target prediction tools miRBase 
(http://microrna.sanger.ac.uk/),  PicTar  (http://pictar.mdc-berlin.de/)  and  TargetScan 
(http://www.targetscan.org/index.html)  were  used  to  identify  potential  microRNA  targets. 
Specifically,  we searched for targets with known expression  in cardiovascular  tissue and 
endothelial cells. We focused on targets predicted by at least two prediction data bases and 
containing a miR-24-8mer seed match in the respective 3’UTR region. 
 
In situ hybridization.  
We combined in situ hybridization of miR-24 with endothelial and smooth muscle cell marker 
stainings. Mouse heart cryosections (10 µm) were dried at room temperature and fixed with 
4% PFA for 10 min. at room temperature and washed two times with DEPC-PBS for 3 min. 
To increase tissue permeability and reduce unspecific background, the sections were treated 
with proteinase K (end concentration 5 µg/ ml) for 15 min at 37°C and then were washed two 
times  for  3  minutes  with  DEPC-PBS.  The  sections  were  acetylated  15  minutes  at  room 
temperature using acetic anhydride dissolved in DEPC- water, 6N HCl and Triethanolamine 
and  subsequently  washed  two  times  with  DEPC-PBS  for  3  min.  Pre-hybridisation  was 
performed 1 hour at 60°C in pre-hybridization buffer containing 50% formamide, 5x SSC, 0.5 
mg/ml yeast tRNA, 1x Denhardt’s solution and 9.2 mM citric acid. Subsequently, sections 
were hybridized with 2.5 pmol of miR-24- specific probe labelled with fluorescein at 5’ end (# 
18121-04, Exiqon) or with fluorescein labelled scrambled miR- probe (#99004-04, Exiqon) 
diluted  in  pre-hybridization  buffer,  overnight  at  60°C.  The  described  RNA  melting 
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temperature of the miR-24 and scrambled control were approximately similar (±3 °C). Next 
day, the sections were washed three times with 0.1x SSC at 65°C  and, finally, one time with 
2x SSC for 5 min, permeabilized for immunostaining with 0.1% Triton X-100 and washed 2 
times with PBS. Unspecific background was blocked with 5% donkey serum diluted in PBS 
30 min. at room temperature. Endothelial cells were stained with rat anti- CD31 antibody (# 
MCA 2388, AbD Serotec) at 1:50 dilution for 2 hours at room temperature and sections were 
washed several times with PBS. Smooth muscle cells were stained with rabbit anti-alpha 
smooth muscle actin antibody (Acta2; ab5694, Abcam) at  1:50 dilution overnight  at  4°C. 
Then,  sections  were  incubated  with  donkey  anti-rat-  AlexaFluor594  antibody  (#21209, 
Invitrogen;  dilution  1:500;  to  detect  Pecam1)  or  with  donkey  anti-rabbit-  AlexaFluor594 
antibody (#21207, Invitrogen dilution 1:500; to detect Acta2) together with DAPI (1: 1000), for 
30 min at  room temperature, washed several times with PBS and mounted the sections 
using VectaShield Hard Set (#H-1400, Vector laboratories) mounting medium.   
 
Immunofluorescence. Frozen heart sections were acetone-fixed, washed and blocked with 
5% (v/v) donkey sera or MOM Mouse IgGs (for RASA1 stain) before addition of appropriate 
Alexa-conjugated  secondary  antibodies  (Invitrogen).  Slides  were  mounted  in 
VECTASHIELD/DAPI  (Linaris,  Germany).  Details  about  used  antibodies  are  shown  in 
Supplemental Table 3. 
 
Chromatin  immunoprecipitation.  Chromatin  immunoprecipitation  (ChIP)  was  used  to 
detect protein-DNA interactions. First, protein G sepharose beads were blocked o/n at 4°C. 
HUVECs from confluent T75 flasks were first cross-linked and harvested. The pellet was 
lysed and sonified to yield DNA fragments from 100-1000 bp in length. Afterwards, samples 
were centrifuged at maximum speed to yield cleared lysates. Aliquots were separately taken 
to  measure  sonification  efficiency  by  agarose  gel  analysis.  To  reduce  non-specific 
background, cleared lysates were pre-cleared on blocked Protein G Sepharose beads (GE 
Healthcare) twice. Samples were subjected to either immunoprecipitation with 5 µg GATA2 
 by guest on August 25, 2011 http://circ.ahajournals.org/ Downloaded from   4 
antibody  (Santa  Cruz  Biotechnology,  sc-267X)  or  control  mouse  IgGs  (Santa  Cruz 
Biotechnology,  sc-2025) o/n  at  4 °C. To block non-specific background BSA and herring 
sperm DNA were added. One sample with cell lysis and IP dilution buffer was used as mock 
control. The next day GATA2/DNA cross-links were collected by incubation with Protein G 
beads. Beads were washed twice with dialysis buffer and four times with IP wash buffer. 
Finally,  beads  were  washed  twice  with  TE-buffer.  Antibody-GATA2/DNA  complexes  were 
eluted from the beads by adding 150 µl IP elution buffer and heating at 65°C. The elution 
step  was  repeated  and  combined  eluates  were  reverse  cross-linked.  Samples  were 
subjected to RNA and protein degradation. Afterwards, DNA was isolated and purified with 
Qiagen PCR purification kit (Qiagen). 
For  ChIP  primer-design  we  first  identified  2000-2500  bp  upstream  promoter  region  of 
candidate target genes by Ensembl Genome Browser (http://www.ensembl.org/index.html). 
Then  we  screened  the  promoter  region  for  potential  GATA2  binding  sites  by  the  use  of 
ALLGEN-Promo and selected appropriate primer pairs that amplify potential GATA2 binding 
sites.  Subsequent  PCR  analysis  of  chipped  DNA  fragments  was  done  by  mixing  2.5  µl 
sample, 2.5 µl 4 µM appropriate primer pairs, 10 µl HotStarTaq Mix (Qiagen) and applying 
the following protocol: 94°C 10 min, [94°C 1 min, 57°C 30 sec, 72°C 1 min]x33, 72°C 10 min, 
4°C hold. Used oligonucleotide primer sequences are given in Supplemental Table 4. 
 
Antagomir  injection.  Antagomirs  were  designed  and  provided  by  Regulus  Therapeutics 
(USA)  and  as  described 
4.  Sequences  were:  Antagomir-24:  5’-
CTGTTCCTGCTGAACTGAGCCA-chol-3’  and  scrambled  Antagomir:  5’-
ACAAACACCAUUGUCACACUCCA-chol-3’. Antagomirs were diluted in nuclease-free water 
and 100 µl at concentrations of 5 mg/kg and 80 mg/kg were applied to mice via retroorbital 
injection. 
 
Determination of apoptotic endothelial cells and cardiomyocytes in vivo. Apoptosis was 
quantified at 14 days after MI by terminal deoxynucleotidyltransferase (TdT)-mediated dUTP 
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nick-end  labeling  (TUNEL)  technique  (in  situ  cell  death  detection kit  Fluorescein,  Roche, 
Germany) and combined cell-type specific stainings of either endothelial cells (Pecam1) or 
cardiomyoctyes (Tnni3). Following treatment of slides with proteinase K (20μg/ml, 30min at 
37°C),  TUNEL  assay  was  performed  as  described  by  the  manufacturer.  Sections  were 
additionally stained with DAPI to recognize nuclei. At least ten high power fields (400x) from 
the peri-infarct zone were analysed.  
 
Myocardial infarction. Male Mice (C57BL/6, 8-10 weeks) underwent coronary artery ligation 
for the production of myocardial infarction (MI). Successful generation of MI after occlusion of 
the left ascending artery was monitored by parallel electrocardiogram (ECG; ST-elevation) 
measurements and impaired wall motion by echocardiography. Only mice with significant ST-
elevation in the ECG analysis and impaired wall motion by echocardiography were included 
in  the  study.  Briefly,  mice  were  anesthetized,  placed  on  a  heating  pad,  intubated  and 
ventilated  with  a  mixture  of  oxygen  and  isoflurane.  After  left  lateral  thoracotomy  and 
exposure of the heart by retractors, the left anterior descending coronary artery (LAD) was 
permanently  ligated.  Successful  production  of  MI  was  checked  by  measurements  of  ST-
elevation  in  electrocardiograms  as  well  as  impaired  left  ventricular  wall  motion  by 
echocardiography. Animals that did not show ST-elevation and impaired left ventricular wall 
motion after myocardial infarction were excluded from further studies. Fourteen days after 
MI,  additional  echocardiography  measurements  were  performed  and  finally  hearts  were 
excised and cut into transverse sections. From the middle ring, sections were cut and stained 
with appropriate antibodies (see above). Cardiac dimensions and function were analyzed by 
pulse–wave Doppler echocardiography. 
 
Determination of infarct size. This was done essentially as described previously 
5. From 
cardiac rings sections were stained with picrosirius red and infarct size was determined by 
planimetric  measurement  using  a  microscope  and  calculated  by  dividing  the  sum  of 
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endocardial and epicardial circumferences of infarct areas by the sum of the total endocardial 
and epicardial circumferences. 
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Additional Figures 
 
Figure legends  
 
Supplemental Figure 1. MiR-24 inhibits endothelial tube formation independently from 
its pro-apoptotic activity but has no effects on number and function of endothelial 
progenitor cells. Endothelial tube formation 72 h after transfection of scrambled miRNAs 
(scr-miR, 100 nM) or miR-24 precursors (pre-miR-24, 100 nM) in the presence or absence of 
a pan-caspase inhibitor (Caspase 3 inhibitor I, 100 µm, 72 h). **P,0.01. n=3-5 per group. 
 
Supplemental Figure 2. Regulation and functional importance of further miR-24 targets 
RASA1 and H2AFX in endothelial cells. (a) Western Blots of RASA1 and H2AFX 72 h after 
transfection of scrambled (scr-miR) or miR-24 precursors (pre-24). (b) Activities of luciferase 
reporter constructs comprising the 3’UTR region of RASA1 and H2AFX mRNA relative to 
beta-Gal control plasmids after transfection of synthetic miRNAs. (c) Western blots of RASA1 
and H2AFX 48 h after transfection of specific siRNAs against RASA1, H2AFX or appropriate 
control siRNAs (si-scr). TBP=TATA box binding protein (nuclear housekeeping protein). (d) 
Relative changes in apoptosis (Annexin V-assay) and changes in tube formation (e) 48h after 
transfection of specific siRNAs against RASA1, H2AFX or appropriate scrambled siRNAs.  
n=3-4  experiments  per  group.  Data  are  mean  and  s.e.m.;  *P,0.05,  ***P,0.005.  
 
Supplemental  Figure  3.  Cardiac  endothelial  expression  of  miR-24  targets.  (a) 
Localization of endothelial protein Pecam1 and the miR-24 targets Gata2, Pak4 and Rasa1 
in sections of mouse hearts. Nuclei were counterstained with 4',6-diamidin-2'-phenylindol-
dihydrochlorid  (DAPI).  White  arrows  indicate  perinuclear  region  of  PAK4  expression  in 
cardiac  endothelial  cells.  (b)  Protein  expression  of  miR-24  targets  in  fractionated 
cardiomyoctyes and cardiac endothelial cells. n=3-4 experiments per group. 
 
Supplemental Figure 4. MiR-24 target modulation in endothelial cells. (a) Expression of 
GATA2  and  PAK4  48h  after  transfection  of  specific  siRNAs  against  GATA2  or  PAK4  or 
scrambled controls (si-scr). Right, Statistical summary. (b) Gata2 expression three days after 
transfection of a murine GFP-Gata2 construct or a YFP-labeled control construct to human 
umbilical vein endothelial cells. Note, cytoplasmic localisation of the control construct and 
nuclear  expression  of the  GFP-Gata2  construct.  (c) Western  blots  of SIRT1  after  up-  or 
downregulation of GATA2 in HUVECs. (d) SIRT1 expression after transfection of increasing 
doses (m.o.i.) of the adenoviral GATA2 construct to endothelial cells. n=3-4 experiments per 
group. Data are mean and s.e.m.; *P,0.05; ***P,0.005.  
 
Supplemental  Figure  5.  MiR-24  regulates  HMOX1  expression  via  GATA2  and  Bad 
phosphorylation via PAK4 in endothelial cells. (a) HMOX1 expression is regulated by 
miR-24 in endothelial cells.(b) GATA2 and HMOX1 expression in endothelial cells after miR-
24 inhibition and/or GATA2 silencing. (c) FACS-based analysis of ROS formation 72 h after 
transfection of synthetic miR-24 precursors (pre-24) or scrambled controls (scr) to HUVECs. 
(d) BAD phosphorylation in endothelial cells after miR-24 inhibition and/or PAK4 silencing. 
n=3-6 experiments per group. Data are mean and s.e.m.; *P,0.05, **P,0.01, ***P,0.005. 
 
Supplemental  Figure  6.  Knockdown  strategy  for  pak4.  (a,b)  Lateral  view  of    24  hpf 
zebrafish embryos injected with (a, a’) cRNA containing Pak4-morpholino target site in front 
of a cassette encoding GFP and 4 ng of control morpholino or (b, b’) cRNA containing Pak4-
morpholino  target  site  in  front  of  a  cassette  encoding  GFP  and  4  ng  of  MO1-pak4.  (a’) 
Whereas  the  control  embryos  displayed  GFP  expression,  (b)  GFP  expression  was 
suppressed by silencing of the Pak4-target site after injection  of MO1-pak4 morpholino. (c) 
The splice site morpholino MO2-pak4 was directed against the exon 5, intron 5 boundary of 
 by guest on August 25, 2011 http://circ.ahajournals.org/ Downloaded from   8 
pak4 which consists of 10 exons. Arrows depict the location of the two primers which were 
utilized in the RT-PCR analysis. RT-PCR analysis of total RNA isolated of MO2-pak4 and 
control morpholino injected embryos at 24 hpf revealed a significant decrease of correctly 
spliced pak4 transcripts in MO2-pak4 morphants in contrast to the control. RT-PCR analysis 
of ß-actin served as loading control. (d) A representative pak4-MO2 injected embryo at 48hpf 
displaying blood accumulation and hemorrhaging (arrows) in the trunk and head region. In 
this particular experiment, 110 embryos were scored and 74 displayed blood retention and 
compromised circulation. 11 embryos had hemorrhages. 
 
Supplemental Figure 7. Prevention of endothelial apoptosis in vivo by antagomir-24 
treatment. Apoptotic endothelial cells (TUNEL
+/Pecam1
+ cells) within the periinfarct region 
14  d  after  myocardial  infarction  (MI)  and  treatment  with  scrambled  antagomirs  (Scr)  or 
antagomir-24 (Ant24). Bottom, Statistical summary. n=6-8 experiments per group. Data are 
mean and s.e.m.; **P,0.01. 
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Additional Tables 
 
Supplemental Table 1: TaqMan miRNA detection assays  
miRNA  Reference 
miR-24  Assay ID 000402, Applied Biosystems, USA 
RNU6-2  Assay ID 001093, Applied Biosystems, USA 
 
Supplemental Table 2: Used siRNAs and miRNAs 
siRNAs 
siRNA  Reference 
GATA2   sc-37228, Santa Cruz Biotechnology, USA 
PAK4   sc-39060, Santa Cruz Biotechnology, USA 
H2AFX  sc-62464, Santa Cruz Biotechnology, USA 
RASA1  sc-29467, Santa Cruz Biotechnology, USA 
Drosha 
6 
scrambled siRNA 
control-A 
sc-37007, Santa Cruz Biotechnology, USA 
 
miRNAs 
miRNA  Reference 
miR-24  PM10737, Applied Biosystems, USA 
anti-miR-24  AM10737, Applied Biosystems, USA 
miR-22  PM11752, Applied Biosystems, USA 
miR-210  PM10516, Applied Biosystems, USA 
pre-miR. precursor 
molecules-negative 
control #2  
PM17111, Applied Biosystems, USA 
 
Supplemental  Table  3:  Antibodies  applied  in  this  work  for  Western  blotting  and 
immunofluorescence 
Antibody  Reference  Immunization 
GAPDH  ab8245, Abcam, USA  mouse 
GATA2   arp31855, Aviva Systems Biology, USA  rabbit 
GFP  ab1218, Abcam, USA  mouse 
HMOX1  AF3776, R&D Systems, USA  goat 
PAK4  ab19007, Abcam, USA  rabbit 
BAD  ab28840, Abcam, USA  rabbit 
RASA1  ab2922, Abcam, USA  mouse 
SIRT1  ab32441, Abcam, USA  rabbit 
H2AFX  ab11175, Abcam, USA  rabbit 
TBP  ab818, Abcam, USA  mouse 
PECAM1  #2388, AbD Serotec, Germany  rat 
TNNI3  sc-15368, Santa Cruz Biotechnology, USA  rabbit 
ACTN2  ab15734, Abcam, USA  rabbit 
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Supplemental Table 4: Primers used for ChIP-PCR 
Promoter region  primer (forward, reverse)  Product size [bp] 
BMP and activin 
membrane-bound 
inhibitor (BAMBI) 
forward: 5´-tctcaggttttggagggaga-3´ 
reverse: 5´-ggccgagactgacactcaat-3´ 
259 
Endothelial cell 
specific molecule 1 
(ESM1) 
forward: 5´- caagtgatatgccagggtca -3´ 
reverse: 5´- tggttgttttgcatgaggac -3´ 
136 
Heme oxygenase 1 
(HMOX1) 
forward: 5´- catcaccagacccagacaga-3´ 
reverse: 5´- aaggccgactttaagggaag-3´ 
133 
Netrin 4 (NTN4)  forward: 5´-gagccagttattcagcaaagaaa-3´ 
reverse: 5´-atgcagaggccatgctaatc-3´ 
180 
Sirtuin 1 (SIRT1)  forward: 5´-ggagtcacagtgtgccagaa-3´ 
reverse: 5´-ccttcctttctagcgtgagc-3´ 
201 
 
Supplemental  Table  5:  Morpholino  sequences  for  target  knockdown  studies  in 
zebrafish 
 
name      sequence 
MO1-gata2a  5' - CATCTACTCACCAGTCTGCGCTTTG - 3' 
MO2-gata2a  5' - AATGAATCCTACCGTGCGCTTGTCC – 3´ 
MO1-pak4  5‘- GCTTTTTCTTGCTGAACATGGC - 3‘ 
MO2-pak4  5‘ – TTCCTGTGTGTTGCACCAACCTCAT – 3‘ 
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